

mTOR (FRAP1) Antibody (S2481)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP6273c

Specification

mTOR (FRAP1) Antibody (S2481) - Product Information

Application	IF, WB, IHC-P,E
Primary Accession	P42345
Other Accession	P42346 , O9JLN9
Reactivity	Human
Predicted	Mouse, Rat
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Antigen Region	2459-2488

mTOR (FRAP1) Antibody (S2481) - Additional Information

Gene ID 2475

Other Names

Serine/threonine-protein kinase mTOR, FK506-binding protein 12-rapamycin complex-associated protein 1, FKBP12-rapamycin complex-associated protein, Mammalian target of rapamycin, mTOR, Mechanistic target of rapamycin, Rapamycin and FKBP12 target 1, Rapamycin target protein 1, MTOR, FRAP, FRAP1, FRAP2, RAFT1, RAPT1

Target/Specificity

This mTOR (FRAP1) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 2459-2488 amino acids from human mTOR (FRAP1).

Dilution

IF~~1:10~50
WB~~1:2000
IHC-P~~1:10~50

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

mTOR (FRAP1) Antibody (S2481) is for research use only and not for use in diagnostic or therapeutic procedures.

mTOR (FRAP1) Antibody (S2481) - Protein Information

Name MTOR ([HGNC:3942](#))

Function Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals (PubMed:[12087098](#), PubMed:[12150925](#), PubMed:[12150926](#), PubMed:[12231510](#), PubMed:[12718876](#), PubMed:[14651849](#), PubMed:[15268862](#), PubMed:[15467718](#), PubMed:[15545625](#), PubMed:[15718470](#), PubMed:[18497260](#), PubMed:[18762023](#), PubMed:[18925875](#), PubMed:[20516213](#), PubMed:[20537536](#), PubMed:[21659604](#), PubMed:[23429703](#), PubMed:[23429704](#), PubMed:[25799227](#), PubMed:[26018084](#), PubMed:[29150432](#), PubMed:[29236692](#), PubMed:[31112131](#), PubMed:[31601708](#), PubMed:[32561715](#), PubMed:[34519269](#), PubMed:[37751742](#)). MTOR directly or indirectly regulates the phosphorylation of at least 800 proteins (PubMed:[15268862](#), PubMed:[15467718](#), PubMed:[17517883](#), PubMed:[18372248](#), PubMed:[18497260](#), PubMed:[18925875](#), PubMed:[20516213](#), PubMed:[21576368](#), PubMed:[21659604](#), PubMed:[23429704](#), PubMed:[29236692](#), PubMed:[37751742](#)). Functions as part of 2 structurally and functionally distinct signaling complexes mTORC1 and mTORC2 (mTOR complex 1 and 2) (PubMed:[15268862](#), PubMed:[15467718](#), PubMed:[18497260](#), PubMed:[18925875](#), PubMed:[20516213](#), PubMed:[21576368](#), PubMed:[21659604](#), PubMed:[23429704](#)). In response to nutrients, growth factors or amino acids, mTORC1 is recruited to the lysosome membrane and promotes protein, lipid and nucleotide synthesis by phosphorylating key regulators of mRNA translation and ribosome synthesis (PubMed:[12087098](#), PubMed:[12150925](#), PubMed:[12150926](#), PubMed:[12231510](#), PubMed:[12718876](#), PubMed:[14651849](#), PubMed:[15268862](#), PubMed:[15467718](#), PubMed:[15545625](#), PubMed:[15718470](#), PubMed:[18497260](#), PubMed:[18762023](#), PubMed:[18925875](#), PubMed:[20516213](#), PubMed:[20537536](#), PubMed:[21659604](#), PubMed:[23429703](#), PubMed:[23429704](#), PubMed:[25799227](#), PubMed:[26018084](#), PubMed:[29150432](#), PubMed:[29236692](#), PubMed:[31112131](#), PubMed:[34519269](#)). This includes phosphorylation of EIF4EBP1 and release of its inhibition toward the elongation initiation factor 4E (eIF4E) (PubMed:[24403073](#), PubMed:[29236692](#)). Moreover, phosphorylates and activates RPS6KB1 and RPS6KB2 that promote protein synthesis by modulating the activity of their downstream targets including ribosomal protein S6, eukaryotic translation initiation factor EIF4B, and the inhibitor of translation initiation PDCD4 (PubMed:[12087098](#), PubMed:[12150925](#), PubMed:[18925875](#), PubMed:[29150432](#), PubMed:[29236692](#)). Stimulates the pyrimidine biosynthesis pathway, both by acute regulation through RPS6KB1-mediated phosphorylation of the biosynthetic enzyme CAD, and delayed regulation, through transcriptional enhancement of the pentose phosphate pathway which produces 5-phosphoribosyl-1- pyrophosphate (PRPP), an allosteric activator of CAD at a later step in synthesis, this function is dependent on the mTORC1 complex (PubMed:[23429703](#), PubMed:[23429704](#)). Regulates ribosome synthesis by activating RNA polymerase III-dependent transcription through phosphorylation and inhibition of MAF1 an RNA polymerase III-repressor (PubMed:[20516213](#)). Activates dormant ribosomes by mediating phosphorylation of SERBP1, leading to SERBP1 inactivation and reactivation of translation (PubMed:[36691768](#)). In parallel to protein synthesis, also regulates lipid synthesis through SREBF1/SREBP1 and LPIN1 (PubMed:[23426360](#)). To maintain energy homeostasis mTORC1 may also regulate mitochondrial biogenesis through regulation of PPARGC1A (By similarity). In the same time, mTORC1 inhibits catabolic pathways: negatively regulates autophagy through phosphorylation of ULK1 (PubMed:[32561715](#)). Under nutrient sufficiency, phosphorylates ULK1 at 'Ser-758', disrupting the interaction with AMPK and preventing activation of ULK1 (PubMed:[32561715](#)). Also prevents autophagy through phosphorylation of the autophagy inhibitor DAP (PubMed:[20537536](#)). Also prevents autophagy by phosphorylating RUBCNL/Pacer under nutrient-rich conditions (PubMed:[30704899](#)). Prevents autophagy by mediating phosphorylation of AMBRA1, thereby inhibiting AMBRA1 ability to mediate ubiquitination of ULK1 and interaction between AMBRA1 and PPP2CA (PubMed:[23524951](#), PubMed:[25438055](#)). mTORC1 exerts a feedback control on upstream growth factor signaling that includes phosphorylation and activation of GRB10 a INSR-dependent signaling suppressor (PubMed:[21659604](#)). Among other potential targets mTORC1 may phosphorylate CLIP1 and regulate microtubules (PubMed:[12231510](#)). The mTORC1 complex is inhibited in response to starvation and amino acid depletion (PubMed:[12150925](#), PubMed:[12150926](#), PubMed:[24403073](#), PubMed:[31695197](#)). The non-canonical mTORC1 complex,

which acts independently of RHEB, specifically mediates phosphorylation of MiT/TFE factors MITF, TFEB and TFE3 in the presence of nutrients, promoting their cytosolic retention and inactivation (PubMed:[22343943](#), PubMed:[22576015](#), PubMed:[22692423](#), PubMed:[24448649](#), PubMed:[32612235](#), PubMed:[36608670](#), PubMed:[36697823](#)). Upon starvation or lysosomal stress, inhibition of mTORC1 induces dephosphorylation and nuclear translocation of TFEB and TFE3, promoting their transcription factor activity (PubMed:[22343943](#), PubMed:[22576015](#), PubMed:[22692423](#), PubMed:[24448649](#), PubMed:[32612235](#), PubMed:[36608670](#)). The mTORC1 complex regulates pyroptosis in macrophages by promoting GSDMD oligomerization (PubMed:[34289345](#)). MTOR phosphorylates RPTOR which in turn inhibits mTORC1 (By similarity). As part of the mTORC2 complex MTOR may regulate other cellular processes including survival and organization of the cytoskeleton (PubMed:[15268862](#), PubMed:[15467718](#)). mTORC2 plays a critical role in the phosphorylation at 'Ser-473' of AKT1, a pro- survival effector of phosphoinositide 3-kinase, facilitating its activation by PDK1 (PubMed:[15718470](#)). mTORC2 may regulate the actin cytoskeleton, through phosphorylation of PRKCA, PXN and activation of the Rho-type guanine nucleotide exchange factors RHOA and RAC1A or RAC1B (PubMed:[15268862](#)). mTORC2 also regulates the phosphorylation of SGK1 at 'Ser-422' (PubMed:[18925875](#)). Regulates osteoclastogenesis by adjusting the expression of CEBPB isoforms (By similarity). Plays an important regulatory role in the circadian clock function; regulates period length and rhythm amplitude of the suprachiasmatic nucleus (SCN) and liver clocks (By similarity).

Cellular Location

Lysosome membrane; Peripheral membrane protein; Cytoplasmic side. Endoplasmic reticulum membrane; Peripheral membrane protein; Cytoplasmic side. Golgi apparatus membrane; Peripheral membrane protein; Cytoplasmic side. Mitochondrion outer membrane; Peripheral membrane protein; Cytoplasmic side. Cytoplasm. Nucleus {ECO:0000250|UniProtKB:Q9JLN9}. Nucleus, PML body {ECO:0000250|UniProtKB:Q9JLN9}. Microsome membrane. Cytoplasmic vesicle, phagosome. Note=Shuttles between cytoplasm and nucleus. Accumulates in the nucleus in response to hypoxia (By similarity). Targeting to lysosomes depends on amino acid availability and RRAGA and RRAGB (PubMed:[18497260](#), PubMed:[20381137](#)). Lysosome targeting also depends on interaction with MEAK7. Translocates to the lysosome membrane in the presence of TM4SF5 (PubMed:[30956113](#)) {ECO:0000250|UniProtKB:Q9JLN9, ECO:0000269|PubMed:[18497260](#), ECO:0000269|PubMed:[20381137](#), ECO:0000269|PubMed:[29750193](#), ECO:0000269|PubMed:[30956113](#)}

Tissue Location


Expressed in numerous tissues, with highest levels in testis.


mTOR (FRAP1) Antibody (S2481) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

mTOR (FRAP1) Antibody (S2481) - Images







Confocal immunofluorescent analysis of mTOR (FRAP1) Antibody (S2481)(Cat#AP6273c) with HeLa cell followed by Alexa Fluor 488-conjugated goat anti-rabbit IgG (green).DAPI was used to stain the cell nuclear (blue).



Western blot analysis of FRAP1 (arrow) using rabbit polyclonal FRAP1 Antibody (S2481) (Cat.#AP6273c). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected with the FRAP1 gene (Lane 2) (Origene Technologies).



All lanes : Anti-FRAP1 Antibody (pS2481) at 1:2000 dilution Lane 1: HeLa whole cell lysate Lane 2: K562 whole cell lysate Lysates/proteins at 20 μ g per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 289 kDa Blocking/Dilution buffer: 5% NFDN/TBST.



Formalin-fixed and paraffin-embedded human testis tissue reacted with FRAP1-pS2481, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.

mTOR (FRAP1) Antibody (S2481) - Background

FRAP1 belongs to a family of phosphatidylinositol kinase-related kinases. These kinases mediate cellular responses to stresses such as DNA damage and nutrient deprivation. This protein acts as the target for the cell-cycle arrest and immunosuppressive effects of the FKBP12-rapamycin complex. FRAP1 is a part of the TORC2 complex which plays a critical role in AKT1 Ser-473 phosphorylation, and may modulate the phosphorylation of PKCA and regulate actin cytoskeleton organization.

mTOR (FRAP1) Antibody (S2481) - References

Dowling,R.J., Cancer Res. 67 (22), 10804-10812 (2007)

Bai,X., Science 318 (5852), 977-980 (2007)

Zhou,J., Proc. Natl. Acad. Sci. U.S.A. 104 (41), 16158-16163 (2007)

Radulovic,S., J BUON 12 SUPPL 1, S151-S162 (2007)

mTOR (FRAP1) Antibody (S2481) - Citations

- [miR-196b-5p controls adipocyte differentiation and lipogenesis through regulating mTORC1 and TGF- \$\beta\$ signaling.](#)
- [Escins Isolated from Bge. Promote the Autophagic Degradation of Mutant Huntingtin and Inhibit its Induced Apoptosis in HT22 cells.](#)
- [Predicting Radiation Resistance in Breast Cancer with Expression Status of Phosphorylated S6K1.](#)
- [Polyphyllin VI, a saponin from Trillium tschonoskii Maxim. induces apoptotic and autophagic cell death via the ROS triggered mTOR signaling pathway in non-small cell lung cancer.](#)
- [miR-1273g-3p promotes proliferation, migration and invasion of LoVo cells via cannabinoid receptor 1 through activation of ERBB4/PIK3R3/mTOR/S6K2 signaling pathway.](#)
- [Orientin protects myocardial cells against hypoxia-reoxygenation injury through induction of autophagy.](#)
- [Overexpression of X-Box Binding Protein 1 \(XBP1\) Correlates to Poor Prognosis and Up-Regulation of PI3K/mTOR in Human Osteosarcoma.](#)
- [MiR-511 inhibits growth and metastasis of human hepatocellular carcinoma cells by targeting PIK3R3.](#)